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Human papillomaviruses and cancer have been a big topic in social media lately, and 
this is an engaging and important topic for all of us. We can prevent infections, and we can 
use different tests to identify cell changes before they become cancerous. With this, I will 
recommend all women to take cervical cell samples every third year, and all those young who 






























Human papillomaviruses (HPVs) are composed of a big group of over hundred related 
viruses. Some of them can cause warts, and some can in worst case lead to cancer. High-risk 
HPVs can cause several types of cancer such as: cervical cancer, anal cancer, oropharyngeal 
cancers (cancers of the middle part of throat, including the soft palate, the base of the tongue, 
and the tonsils), vaginal cancer, vulvar cancer and penile cancer. 
The high-risk HPVs cause approximately 5 % of all cancers worldwide. It is well 
known that oral cancer is related to tobacco and alcohol use. On the other hand, HPVs seem 
to be linked to many of the cases of oral cancer. In Norway 57 % of oropharyngeal cancers 
are related to HPV infections. Nearly 70 % of all humans will be infected by HPV during life. 
Most of HPV infections go away on their own, but some infections persist and can cause 
cellular changes in the infected tissues. 
The identification of HPV nowadays relies on molecular biology techniques. This is 
because it cannot be propagated in tissue cultures. HPV has a well-known physical structure 
and an organization of genes, making the tests of choice for detecting HPV from clinical 
specimens based on nucleic acid probe technology. The detection methods can be divided into 
target amplification methods and signal amplification methods. Polymerase chain reaction 
(PCR) is the most commonly used tool in the detection of HPVs DNA. 
Since 2009, a vaccine (Gardasil) against 4 types of HPVs has been offered to 12-year-
old females in Norway. The main purpose of this vaccine was to prevent the occurrence of 
cervical cancer among Norwegian females. It is estimated that 100 % of all cervical cancers 
are related to HPV infections. About 10 000 Norwegian females get diagnosed with mild 
cervical cell changes every year. About 300 Norwegian females are diagnosed with cervical 
cancer each year, and every year about 70 Norwegian females die because of cervical cancer. 
HPV 16 and 18 are considered the main cause of about 70 % of cervical cancer, and HPV 6 
and 11 are found in cases mostly related to genital warts. The HPV vaccine is now also 
offered to Norwegian females born between year 1991 and 1996, 20-25 years of age. Some 
studies have suggested that the HPV vaccine can protect against HPV infections caused by 











1.1 Introduction: Human papillomaviruses 
 
Human papillomaviruses (HPVs) are composed of a big group of over hundred related 
viruses (1). Some of them can cause warts, and some can in worst case lead to cancer. They 
can be spread through sexual and non-sexual contact, depending on the virus. About 40 HPV 
types can transmit through direct sexual contact, from the skin and mucous membranes of the 
infected people to the skin and mucous membranes of their partners (2). Most of HPV 
infections go away on their own, without any signs or symptoms. This means also that 
infected people can unknowingly pass HPV to their sexual partners (3). Nearly 70 % of all 
humans will be infected by HPV during life (4). Some people get persistent infections with 






Figure 1. Human Papillomavirus shown under an electron microscope(6) 
 
 





1.2 The link between HPV and cancer 
  
 
The Human papillomavirus was first discovered in 1956, by a group of scientists. At 
that time, it was difficult to investigate the virus and study the individual viral genes, because 
of the lack of cloning techniques (7).  
There had for a long time been seen a potential link between a viral infection and 
cervical cancer. When scientists did their search, it was important to compare the lifestyle of 
women with cervical cancer and women without the disease. The observation was surprising. 
They found that prostitutes had a high risk of getting the disease, married women had a 
moderate risk, and nuns were mostly spared from it (8). The risk of cervical cancer correlated 
with the number of sexual partners, which suggested that a sexual transmitted agent played an 
important role.   
The search of the viral agent causing cervical cancer lasted many years. There were 
many diseases and viral infections that made a false lead in finding the cause. But in the 
1980s the German virologist Harald Zur Hausen did a big discovery (7). Harald Zur Hausen 
had heard about the papillomavirus in rabbits, a research done by Richard Shope from the 
1930s (8). Richard Shope found that rabbits with horns growing out of their body had an 
infection. He found that they were infected with a type of papillomavirus, that caused warts 
(horns) and cancer in rabbits (9). Harald Zur Hausen began to search for a similar virus that 
could infect humans. He then found HPV 6 in genital warts (10). But after more research it 
was clear that this virus was rarely found in cases with cancer. It was neither the same virus 
causing warts on hands or feet. This made him think of the possibility that there could be 
several types of HPVs, causing different symptoms, virulence, and malignancy. Harald Zur 
Hausen managed to clone DNA from cervical cancer tissues. Sequence analysis of the DNA 
revealed new strains of HPV, HPV 16 and HPV 18 (11, 12). After analyzing many women 
with cervical cancer, they found that 70 % of them had cancer cells containing these two 
types of HPV. By the end of the 20th century, over 100 types of HPV were identified (7). And 
today we know that the prevalence of HPV DNA in cervical cancer approaches nearly 100 % 
(13). In 2008, Harald Zur Hausen received the Nobel Prize for his discovery of human 
papilloma viruses causing cervical cancer (8). 
 





1.3 Low-risk HPVs and high-risk HPVs  
 
 
We can divide HPVs into low-risk HPVs and high-risk HPVs. Low-risk HPVs are the 
types that can cause warts(14). HPV 6 and HPV 11 are found in 90% of genital warts. These 
viruses can transmit by direct sexual contact like vaginal-, anal-, and oral sex, and when skin 
or mucous membranes are in contact (5). These viruses can be transmitted before any sexual 
intercourse, and even with the use of prevention measures like condoms. This is because 
infected skin can be in contact with healthy skin, and transmit the virus. The warts can arise 
on the genitals, around the anus, mouth, or throat. These two viruses can also lead to a rare 
condition called recurrent respiratory papillomatosis (RRP)(15). This disease causes 
symptoms in the upper respiratory airway. Warty growths, benign tumors, may lead to 
significant airway destruction or change of voice. Kids age 5 years or younger are likely to 
have get infected during the period of their childbirth, while adults seem to get it from sexual 
transmission(16). 
 
On the other hand, high-risk HPVs can cause several types of cancer such as: cervical 
cancer, anal cancer, oropharyngeal cancers (cancers of the middle part of throat, including the 
soft palate, the base of the tongue, and the tonsils), vaginal cancer, vulvar cancer and penile 
cancer (5). The term high-risk is based on whether they put a person at risk of developing 
cancer or not(14). These viruses can transmit by direct sexual contact like vaginal-, anal-, and 
oral sex, and when skin or mucous membranes are in contact. HPV 16 and HPV 18 are 
responsible for most HPV-caused cancers. It is estimated that the high-risk HPVs cause 
approximately 5 % of all cancers worldwide (5). There are several factors that can contribute 
in the persisting of a high-risk infection of HPV, and the developing of cancer. The factors 
that increase the risk are smoking, weakened immune system, early sexual debut, multiple 













1.4 Structure of the Human papillomavirus 
 
 
HPVs are small non-enveloped DNA viruses (19). The circular, double stranded viral 
genome consists of approximately 8 kb. The viruses have a diameter of 52-55 nm (20). The 
genome encodes for six early proteins responsible for virus replication and two late proteins, 
L1 and L2, which are the viral structural proteins. Papillomaviruses replicate and assemble 
exclusively in the nucleus (21).  
 
The Viruses infect the keratinocytes in the basal layers of stratified squamous 
epithelium. The replication and expression of the viral gene is proceeded in a controlled 
fashion, and are regulated by keratinocyte differentiation. This process is not fully 
understood, but there is a general agreement about the six regulatory proteins (E1, E2, E4, E5, 
E6 and E7) and two viral structural capsid proteins (L1 and L2) (16). E1 and E2 are involved 
in the DNA replication of the viral DNA and the regulation of the early transcription. They 
act as factors that recognize the origin of replication, where E2 also is the main regulator of 
the viral gene transcription (20). E4 associates with cytokeratin filament collapse, when 
expressed in a productive infection. The E4 protein is believed to be involved in the late 
stages of life cycle of the virus, and continues to be expressed in the terminally differentiated 
keratinocytes (19, 20). E5 expression induces cell immortalization and transformation. E5 
may function during both the early and the late face(19, 20). Two of them, E6 and E7, are 
viral oncoproteins. They inactivate p53 and pRb, which are cellular tumor suppressor proteins 
(22, 23). L1 and L2 encapsidate the viral genomes to form progeny virions in the nucleus. The 






















L1 MAJOR CAPSID 
PROTEIN 
4775-6292 5430-7136 
L2 MINOR CAPSID 
PROTEIN 
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E1 DNA REPLICATION, 
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epitheliotropic, and they establish 
productive infections only within 
stratified epithelia of the skin, oral 
cavity, and the anogenital tract (19). 
The viral life cycle is linked to the 
differentiation of the infected 
epithelial cell. The progression of 
untreated lesions to invasive cancer 
is associated with the integration of 
the HPV genome into the host 
chromosomes, with associated loss or Figure 2. HPV 16 





disruption of E2, and upregulation of E6 and E7 oncogene expression. E6 and E7 from low-
risk HPVs, inactivate cellular p53 and pRb tumor suppressor proteins less efficiently than E6 




















1.5 Comparison of HPV 16 and HPV 18 genomes 
 
When comparing HPV 16 and HPV 18 we can see that they do not have any identical 
genome, but parts of it has somewhat similar sequences. The red areas in the table below are 






Figure 4. Comparison of HPV 16 and HPV 18 (64) 
 
 
The vaccines have been made with virus-like particles (VLPs) of the recombinant 
major capsid (L1). When we compare L1 of HPV 16 and HPV 18 in the figure beneath, we 
see that the alignment score is high, and that is why they can use particles resembling this area 





















 The identification of HPV nowadays relies on molecular biology techniques. This is 
because it cannot be propagated in tissue cultures. HPV has a well-known physical structure 
and an organization of genes, making the tests of choice for detecting HPV from clinical 
specimens based on nucleic acid probe technology(23). The detection methods can be divided 




2.1 Target amplification methods 
a) Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is the most commonly used tool in the detection of 
HPVs DNA. In this detection system, a spectrum of HPV types is amplified by consensus 
primers, followed by detection with type-specific probes. These techniques are specific, 
highly sensitive, and widely used(25). The thermostable DNA polymerase recognizes and 
extends a pair of oligonucleotide primers that flank the region of interest. PCR can 
theoretically produce one billion copies from a single double-stranded DNA molecule after 30 
cycles of amplification(26). Typically, PCR procedures for HPV detection use primers 
targeted to the viral capsid L1 gene, which can detect numerous HPV types. Commonly used 
L1 consensus primer sets include PGMY09/11, GP5+/6+, and SPF10, along with a few 















Table 2. Examples of primers used to identify HPV16 and HPV18(63) 
 
TYPE PRIMER SEQUENCE POSITION 
HPV16 PR1 5’- TCA AAA GCC 
ACT GTG TCC 
TGA- 3’ 
421-440 
HPV16 PR2 5’- CGT GTT CTT 
GAT GAT CTG 
CAA- 3’ 
521-540 
HPV18 PR1 5’- CCG AGC 
ACG ACA GGA 
ACG ACT-3’ 
533-555 
HPV18 PR2 5’- TCG TTT TCT 
TCC TCT GAG 







Typing of PCR products was traditionally done by means of Southern blotting and in-
situ hybridization with type-specific oligonucleotides(24).  
 
b) Southern blot 
For HPV genome analysis, hybridization in solid phase, such as Southern blot for 
DNA, is an excellent procedure that can generate information with quality, but it is time 
consuming. It requires large amounts of highly purified nucleic acids and well preserved, full-
size molecules. Southern blotting is the transfer of DNA fragments from an electrophoresis 
gel to a membrane support, resulting in immobilization of the DNA fragments, so the 
membrane carries a semi-permanent reproduction of the banding pattern of the gel. After 
immobilization, the DNA can be subjected to hybridization analysis, enabling bands with 










c) In-situ Hybridization 
In-Situ Hybridization (ISH) is a technique that allows for precise localization of a 
specific segment of nucleic acid within a histologic section. The underlying basis of ISH is 
that nucleic acids, if preserved adequately within a histologic specimen, can be detected 
through the application of a complementary strand of nucleic acid to which a reporter 
molecule is attached(37). Like Southern blot, this technique needs large amount of purified 
DNA, and is very time consuming. A disability is that this technique has a low sensitivity (35, 
38-40). 
 
d) Type-specific PCR  
It is possible to find specific types of HPV, by designing primers. With real-time PCR 
assay, we can quantify the HPV in the specimen. Cervical smear can be analyzed by real-time 
PCR, and the amount of high risk HPV is predictive for the presence or development of high-
grade cervical lesions(24). Smear tests (pap test) are used for cervical screening. Samples of 
cells from the cervix can be collected and examined for early cell changes. With this test, it is 
possible to detect cell changes before they are becoming cancerous(33, 41-43). 
 
e) mRNA amplification 
Recently it has been shown that viral mRNA can be detected, and therefore a method 
for finding HPV. The transcripts that are relevant in the search, are the viral oncoproteins E6 
and E7. A hypothesis suggests that viral mRNA from these oncogenes in smear from the 
cervix have a better positive predictive value for high-grade cervical lesions than the presence 
of viral DNA. The explanation is that E6/E7 mRNA represent an active infection with cell-
transforming potential, whereas viral DNA can be present in clinically irrelevant conditions as 
well. Detection of mRNA can be done by reverse-transcriptase PCR or nucleic acid sequence-









2.2 Signal amplification methods 
 
a) Liquid-phase signal amplification techniques 
An example of this type of detection is Hybrid Capture 2 (HC2). This high-risk HPV 
DNA test is a nucleic acid hybridization assay with signal amplification that utilizes 
microplate chemiluminescent detection. This method uses a cocktail of full-length RNA 
probes representing the high-risk HPV searched for(24). The resultant RNA: DNA hybrids 
are captured onto the surface of a microplate well coated with antibodies specific for RNA: 
DNA hybrids. Immobilized hybrids are then reacted with alkaline phosphatase conjugated 
antibodies specific for the RNA: DNA hybrids, and detected with a chemiluminescent 
substrate. Several alkaline phosphatase molecules are conjugated to each antibody. Multiple 
conjugated antibodies bind to each captured hybrid resulting in substantial signal 
amplification. As the substrate is cleaved by the bound alkaline phosphatase, light is emitted 
that is measured as relative light units (RLUs) on a luminometer. The intensity of the light 
emitted denotes the presence or absence of target DNA in the specimen(47) 
 
2.3 Clinical specimen  
 
Detection with PCR can generally use all kinds of clinical specimen, if the DNAs 
contained within are not heavily degraded, cross-linked, or with presence of PCR-inhibiting 
factors(24). It is possible to use saliva, paraffin-fixed/paraffin embedded tissue, and smears to 
















3. HPV related to cancer 
 
3.1 HPV: Oral cancer 
 
Oral cancer is classified as head and neck cancer and head and neck squamous cell carcinoma 
(HNSCC)(48). HPV 16 is the human papilloma virus which is mostly associated with malign 
lesions in the oral cavity(49). HPV- related cancers have a better prognosis than HPV-
negative tumors in overall survival rates and clinical response to treatment. There have been 
found 24 types of HPV associates with benign lesions, and 12 different types associated with 
malign lesions. About 99 % of HPV infections in HNSCC are related to the high-risk types 
HPV-16, HPV-18, HPV-31, and HPV-33. Most of the infections are related to HPV-16, and 
HPV-33 second most with up to 10% of the cases (48). 
 
3.2 HPV: Presence in Norway 
 
Nearly 70 % of all humans will be infected by HPV during life (4). It is well known 
that oral cancer is related to tobacco and alcohol use. On the other hand, HPVs seem to be 
linked to many of the cases of oral cancer(50). In Norway 57 % of oropharyngeal cancers are 
related to HPV infections (statistics from 2014) (4).   
 
Approximately 600 causes of cancer in Norway can be related to a HPV infection. 
Today it is more infection of these viruses among people than previously reported. This can 
be related to the changes in sexual behavior, and an increase in the number of sexual partners. 
It is important to remember that only one sexual partner is enough to be in the risk of getting 











3.3 HPV, cervical cell changes, and cancer in Norway 
 
HPV is very relevant in the relation to cervical cancer in women. It is estimated that 
100 % of all cervical cancers are related to HPV infections. About 10 % of all Norwegian 
women will get genital warts before the age of 45. About 10 000 Norwegian females get 
diagnosed with mild cervical cell changes every year. 3000 Norwegian women get severe cell 
changes every year, that lead to removal of cells in the cervix. This will raise the risk of 
spontaneous abortion and early births. About 300 Norwegian females are diagnosed with 
cervical cancer each year, and every year about 70 Norwegian females die because of cervical 
cancer. There are also 300 other cases of cancer related to HPV, in both men and woman each 
year. These statistics are obtained from analysis of cases in 2014(4). 
 
 
3.4 HPV related to cancer in Norway 
 
In year 2014, 338 Norwegian women were diagnosed with cervical cancer. 100 % of 
these cases were related to a HPV infection. A total of 61 Norwegian women and 25 
Norwegian men were the same year diagnosed with anal cancer. Approximately, 90 % of 
these cases were related to an infection of HPV. In addition, 19 Norwegian women were in 
2014 diagnosed with vaginal cancer, 81 % of these women had an infection of HPV. 39 
Norwegian women and 133 Norwegian men were diagnosed with oropharyngeal cancer, and 
57 % of these cases were seen in relation to a HPV infection. On the other hand, 54 
Norwegian men were diagnosed with penile cancer, 47% were related to an infection of HPV. 
Furthermore, 89 Norwegian women were in 2014 diagnosed with vulva cancer, 29 % of the 
















4.1 Vaccination in Norway 
 
Today we have three different vaccines against HPVs. The vaccines consist of non-
living material, which resemble the surface of the Human papilloma virus. The virus-like 
particles comprising the major capsid protein L1 of the high-risk HPV-16 and HPV-18(51). 
The vaccines cannot cause a HPV infection(52). 
 
In Norway 12-year-old females can get the vaccine through the vaccination program. 
The vaccine has been available in the program since 2009(53). This vaccination is done to 
prevent cervical cancer. HPV is also related to other cancers, so the Government of Norway 
suggest to offer 12-year-old males the vaccine as well(54). 
 
The vaccine cannot remove a persistent infection, so it is advisable to vaccinate before 
sexual debut. The vaccine protects against several types of HPV, so even if you have had an 
infection or not, it can prevent you from getting a new infection or an infection from one of 
the other types of HPV. Therefore, the Government of Norway offers girls born after 1991 the 
vaccine for free (November, 2016)(53). 
 
4.2 Vaccination of young males 
 
The suggestion to offer young males the HPV vaccine is a step in the right direction. 
HPVs are mostly something people relate to women and cervical cancer, but new knowledge 
show us that HPVs are related to so many other types of cancer. It is important to prevent 
both sex from getting infected from these viruses, if we want to stop the progression of HPV-
induced cell changes. The high-risk virus can transmit by all sorts of sexual contact, and we 
live in a society where sexual relations are between individuals with opposite gender or with 
the same gender. That is one of the good arguments why vaccination of only women is not 
enough. Men also need to be protected from cancers associated with HPV(55-57). 





4.3 Contents and protection  
 
All three vaccines available protect against HPV16 and HPV18, which cause 70% of 
all cervical cancers. Cervarix is the commercial name of the vaccine which only protect 
against these two types of HPV. All females between 16 and 25 years of age are offered this 
vaccine. Females younger than 16 years, get the vaccine called Gardasil, which protect 
against HPV16 and HPV18, together with HPV6 and HPV11. The last two HPVs can cause 
90 % of all genital warts, also called condylomas(53). The last vaccine is not available in 
Norway yet, but it protects against nine types of HPV; HPV6, HPV11, HPV16, HPV18, 
HPV31, HPV33, HPV45, HPV52, HPV58. Beside HPV6 and HPV11, these are high-risk 






Figure 6.  Cervarix and Gardasil 
 
| Gardasil contains virus-like particles (VLPs) of the recombinant major capsid (L1) 
protein of HPV types 6, 11, 16, and 18. These are the active substances in the vaccine. The 
recombinant proteins forming the VLPs are produced by separate fermentation in 
recombinant Saccharomyces cerevisiae. The viral proteins are manufactured in yeast cells. 
Once released from yeast cells, the VLPs are purified. VLPs of each type are adsorbed on 
amorphous aluminium hydroxyphosphate sulfate adjuvant. The formulation also includes 
sodium chloride, L-histidine, polysorbate 80, sodium borate, and water for injection. The final 
product is presented as a sterile suspension, either in a single-dose vial or in a prefilled 
syringe for intramuscular injection(58). Gardasil is given in three doses, month 0, 2, and 6. 






The HPV vaccine gives a 90 % protection against the HPVs it is supposed to protect against. 
It has been tested for a period now, and we know that the vaccine protects individuals for at 
least a decade. Some believe it can protect a person throughout life. But it has not been tested 
long enough to know if people will need to get a booster-dose to make it last longer or 
not(52). 
 
Even though vaccination protect against some HPVs it will still be important for women to 
take cell samples from the cervix, every third year after the age of 25. This is because the 
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6. Appendix I 
 
6.1 Human papillomavirus type 16, complete genome 
ORIGIN       
        1 atggctgatc ctgcaggtac caatggggaa gagggtacgg gatgtaatgg atggttttat 
       61 gtagaggctg tagtggaaaa aaaaacaggg gatgctatat cagatgacga gaacgaaaat 
      121 gacagtgata caggtgaaga tttggtagat tttatagtaa atgataatga ttatttaaca 
      181 caggcagaaa cagagacagc acatgcgttg tttactgcac aggaagcaaa acaacataga 
      241 gatgcagtac aggttctaaa acgaaagtat ttgggtagtc cacttagtga tattagtgga 
      301 tgtgtagaca ataatattag tcctagatta aaagctatat gtatagaaaa acaaagtaga 
      361 gctgcaaaaa ggagattatt tgaaagcgaa gacagcgggt atggcaatac tgaagtggaa 
      421 actcagcaga tgttacaggt agaagggcgc catgagactg aaacaccatg tagtcagtat 
      481 agtggtggaa gtgggggtgg ttgcagtcag tacagtagtg gaagtggggg agagggtgtt 
      541 agtgaaagac acactatatg ccaaacacca cttacaaata ttttaaatgt actaaaaact 
      601 agtaatgcaa aggcagcaat gttagcaaaa tttaaagagt tatacggggt gagtttttca 
      661 gaattagtaa gaccatttaa aagtaataaa tcaacgtgtt gcgattggtg tattgctgca 
      721 tttggactta cacccagtat agctgacagt ataaaaacac tattacaaca atattgttta 
      781 tatttacaca ttcaaagttt agcatgttca tggggaatgg ttgtgttact attagtaaga 
      841 tataaatgtg gaaaaaatag agaaacaatt gaaaaattgc tgtctaaact attatgtgtg 
      901 tctccaatgt gtatgatgat agagcctcca aaattgcgta gtacagcagc agcattatat 
      961 tggtataaaa caggtatatc aaatattagt gaagtgtatg gagacacgcc agaatggata 
     1021 caaagacaaa cagtattaca acatagtttt aatgattgta catttgaatt atcacagatg 
     1081 gtacaatggg cctacgataa tgacatagta gacgatagtg aaattgcata taaatatgca 
     1141 caattggcag acactaatag taatgcaagt gcctttctaa aaagtaattc acaggcaaaa 
     1201 attgtaaagg attgtgcaac aatgtgtaga cattataaac gagcagaaaa aaaacaaatg 
     1261 agtatgagtc aatggataaa atatagatgt gatagggtag atgatggagg tgattggaag 
     1321 caaattgtta tgtttttaag gtatcaaggt gtagagttta tgtcattttt aactgcatta 
     1381 aaaagatttt tgcaaggcat acctaaaaaa aattgcatat tactatatgg tgcagctaac 
     1441 acaggtaaat cattatttgg tatgagttta atgaaatttc tgcaagggtc tgtaatatgt 
     1501 tttgtaaatt ctaaaagcca tttttggtta caaccattag cagatgccaa aataggtatg 
     1561 ttagatgatg ctacagtgcc ctgttggaac tacatagatg acaatttaag aaatgcattg 
     1621 gatggaaatt tagtttctat ggatgtaaag catagaccat tggtacaact aaaatgccct 





     1681 ccattattaa ttacatctaa cattaatgct ggtacagatt ctaggtggcc ttatttacat 
     1741 aatagattgg tggtgtttac atttcctaat gagtttccat ttgacgaaaa cggaaatcca 
     1801 gtgtatgagc ttaatgataa gaactggaaa tcctttttct caaggacgtg gtccagatta 
     1861 agtttgcacg aggacgagga caaggaaaac gatggagact ctttgccaac gtttaaatgt 
     1921 gtgtcaggac aaaatactaa cacattatga aaatgatagt acagacctac gtgaccatat 
     1981 agactattgg aaacacatgc gcctagaatg tgctatttat tacaaggcca gagaaatggg 
     2041 atttaaacat attaaccacc aggtggtgcc aacactggct gtatcaaaga ataaagcatt 
     2101 acaagcaatt gaactgcaac taacgttaga aacaatatat aactcacaat atagtaatga 
     2161 aaagtggaca ttacaagacg ttagccttga agtgtattta actgcaccaa caggatgtat 
     2221 aaaaaaacat ggatatacag tggaagtgca gtttgatgga gacatatgca atacaatgca 
     2281 ttatacaaac tggacacata tatatatttg tgaagaagca tcagtaactg tggtagaggg 
     2341 tcaagttgac tattatggtt tatattatgt tcatgaagga atacgaacat attttgtgca 
     2401 gtttaaagat gatgcagaaa aatatagtaa aaataaagta tgggaagttc atgcgggtgg 
     2461 tcaggtaata ttatgtccta catctgtgtt tagcagcaac gaagtatcct ctcctgaaat 
     2521 tattaggcag cacttggcca accaccccgc cgcgacccat accaaagccg tcgccttggg 
     2581 caccgaagaa acacagacga ctatccagcg accaagatca gagccagaca ccggaaaccc 
     2641 ctgccacacc actaagttgt tgcacagaga ctcagtggac agtgctccaa tcctcactgc 
     2701 atttaacagc tcacacaaag gacggattaa ctgtaatagt aacactacac ccatagtaca 
     2761 tttaaaaggt gatgctaata ctttaaaatg tttaagatat agatttaaaa agcattgtac 
     2821 attgtatact gcagtgtcgt ctacatggca ttggacagga cataatgtaa aacataaaag 
     2881 tgcaattgtt acacttacat atgatagtga atggcaacgt gaccaatttt tgtctcaagt 
     2941 taaaatacca aaaactatta cagtgtctac tggatttatg tctatatgac aaatcttgat 
     3001 actgcatcca caacattact ggcgtgcttt ttgctttgct tttgtgtgct tttgtgtgtc 
     3061 tgcctattaa tacgtccgct gcttttgtct gtgtctacat acacatcatt aataatattg 
     3121 gtattactat tgtggataac agcagcctct gcgtttaggt gttttattgt atatattata 
     3181 tttgtttata taccattatt tttaatacat acacatgcac gctttttaat tacataatgt 
     3241 atatgtacat aatgtaattg ttacatataa ttgttgtata ccataactta ctattttttc 
     3301 ttttttattt tcatatataa tttttttttt tgtttgtttg tttgtttttt aataaactgt 
     3361 tattacttaa caatgcgaca caaacgttct gcaaaacgca caaaacgtgc atcggctacc 
     3421 caactttata aaacatgcaa acaggcaggt acatgtccac ctgacattat acctaaggtt 
     3481 gaaggcaaaa ctattgctga tcaaatatta caatatggaa gtatgggtgt attttttggt 
     3541 gggttaggaa ttggaacagg gtcgggtaca ggcggacgca ctgggtatat tccattggga 
     3601 acaaggcctc ccacagctac agatacactt gctcctgtaa gacccccttt aacagtagat 





     3661 cctgtgggcc cttctgatcc ttctatagtt tctttagtgg aagaaactag ttttattgat 
     3721 gctggtgcac caacatctgt accttccatt cccccagatg tatcaggatt tagtattact 
     3781 acttcaactg ataccacacc tgctatatta gatattaata atactgttac tactgttact 
     3841 acacataata atcccacttt cactgaccca tctgtattgc agcctccaac acctgcagaa 
     3901 actggagggc attttacact ttcatcatcc actattagta cacataatta tgaagaaatt 
     3961 cctatggata catttattgt tagcacaaac cctaacacag taactagtag cacacccata 
     4021 ccagggtctc gcccagtggc acgcctagga ttatatagtc gcacaacaca acaggttaaa 
     4081 gttgtagacc ctgcttttgt aaccactccc actaaactta ttacatatga taatcctgca 
     4141 tatgaaggta tagatgtgga taatacatta tatttttcta gtaatgataa tagtattaat 
     4201 atagctccag atcctgactt tttggatata gttgctttac ataggccagc attaacctct 
     4261 aggcgtactg gcattaggta cagtagaatt ggtaataaac aaacactacg tactcgtagt 
     4321 ggaaaatcta taggtgctaa ggtacattat tattatgatt taagtactat tgatcctgca 
     4381 gaagaaatag aattacaaac tataacacct tctacatata ctaccacttc acatgcagcc 
     4441 tcacctactt ctattaataa tggattatat gatatttatg cagatgactt tattacagat 
     4501 acttctacaa ccccggtacc atctgtaccc tctacatctt tatcaggtta tattcctgca 
     4561 aatacaacaa ttccttttgg tggtgcatac aatattcctt tagtatcagg tcctgatata 
     4621 cccattaata taactgacca agctccttca ttaattccta tagttccagg gtctccacaa 
     4681 tatacaatta ttgctgatgc aggtgacttt tatttacatc ctagttatta catgttacga 
     4741 aaacgacgta aacgtttacc atattttttt tcagatgtct ctttggctgc ctagtgaggc 
     4801 cactgtctac ttgcctcctg tcccagtatc taaggttgta agcacggatg aatatgttgc 
     4861 acgcacaaac atatattatc atgcaggaac atccagacta cttgcagttg gacatcccta 
     4921 ttttcctatt aaaaaaccta acaataacaa aatattagtt cctaaagtat caggattaca 
     4981 atacagggta tttagaatac atttacctga ccccaataag tttggttttc ctgacacctc 
     5041 attttataat ccagatacac agcggctggt ttgggcctgt gtaggtgttg aggtaggtcg 
     5101 tggtcagcca ttaggtgtgg gcattagtgg ccatccttta ttaaataaat tggatgacac 
     5161 agaaaatgct agtgcttatg cagcaaatgc aggtgtggat aatagagaat gtatatctat 
     5221 ggattacaaa caaacacaat tgtgtttaat tggttgcaaa ccacctatag gggaacactg 
     5281 gggcaaagga tccccatgta ccaatgttgc agtaaatcca ggtgattgtc caccattaga 
     5341 gttaataaac acagttattc aggatggtga tatggttgat actggctttg gtgctatgga 
     5401 ctttactaca ttacaggcta acaaaagtga agttccactg gatatttgta catctatttg 
     5461 caaatatcca gattatatta aaatggtgtc agaaccatat ggcgacagct tattttttta 
     5521 tttacgaagg gaacaaatgt ttgttagaca tttatttaat agggctggta ctgttggtga 
     5581 aaatgtacca gacgatttat acattaaagg ctctgggtct actgcaaatt tagccagttc 





     5641 aaattatttt cctacaccta gtggttctat ggttacctct gatgcccaaa tattcaataa 
     5701 accttattgg ttacaacgag cacagggcca caataatggc atttgttggg gtaaccaact 
     5761 atttgttact gttgttgata ctacacgcag tacaaatatg tcattatgtg ctgccatatc 
     5821 tacttcagaa actacatata aaaatactaa ctttaaggag tacctacgac atggggagga 
     5881 atatgattta cagtttattt ttcaactgtg caaaataacc ttaactgcag acgttatgac 
     5941 atacatacat tctatgaatt ccactatttt ggaggactgg aattttggtc tacaacctcc 
     6001 cccaggaggc acactagaag atacttatag gtttgtaaca tcccaggcaa ttgcttgtca 
     6061 aaaacataca cctccagcac ctaaagaaga tccccttaaa aaatacactt tttgggaagt 
     6121 aaatttaaag gaaaagtttt ctgcagacct agatcagttt cctttaggac gcaaattttt 
     6181 actacaagca ggattgaagg ccaaaccaaa atttacatta ggaaaacgaa aagctacacc 
     6241 caccacctca tctacctcta caactgctaa acgcaaaaaa cgtaagctgt aagtattgta 
     6301 tgtatgttga attagtgttg tttgttgtgt atatgtttgt atgtgcttgt atgtgcttgt 
     6361 aaatattaag ttgtatgtgt gtttgtatgt atggtataat aaacacgtgt gtatgtgttt 
     6421 ttaaatgctt gtgtaactat tgtgtcatgc aacataaata aacttattgt ttcaacacct 
     6481 actaattgtg ttgtggttat tcattgtata taaactatat ttgctacatc ctgtttttgt 
     6541 tttatatata ctatattttg tagcgccagc ggccattttg tagcttcaac cgaattcggt 
     6601 tgcatgcttt ttggcacaaa atgtgttttt ttaaatagtt ctatgtcagc aactatggtt 
     6661 taaacttgta cgtttcctgc ttgccatgcg tgccaaatcc ctgttttcct gacctgcact 
     6721 gcttgccaac cattccattg ttttttacac tgcactatgt gcaactactg aatcactatg 
     6781 tacattgtgt catataaaat aaatcactat gcgccaacgc cttacatacc gctgttaggc 
     6841 acatattttt ggcttgtttt aactaaccta attgcatatt tggcataagg tttaaacttc 
     6901 taaggccaac taaatgtcac cctagttcat acatgaactg tgtaaaggtt agtcatacat 
     6961 tgttcatttg taaaactgca catgggtgtg tgcaaaccgt tttgggttac acatttacaa 
     7021 gcaacttata taataatact aaactacaat aattcatgta taaaactaag ggcgtaaccg 
     7081 aaatcggttg aaccgaaacc ggttagtata aaagcagaca ttttatgcac caaaagagaa 
     7141 ctgcaatgtt tcaggaccca caggagcgac ccagaaagtt accacagtta tgcacagagc 
     7201 tgcaaacaac tatacatgat ataatattag aatgtgtgta ctgcaagcaa cagttactgc 
     7261 gacgtgaggt atatgacttt gcttttcggg atttatgcat agtatataga gatgggaatc 
     7321 catatgctgt atgtgataaa tgtttaaagt tttattctaa aattagtgag tatagacatt 
     7381 attgttatag tttgtatgga acaacattag aacagcaata caacaaaccg ttgtgtgatt 
     7441 tgttaattag gtgtattaac tgtcaaaagc cactgtgtcc tgaagaaaag caaagacatc 
     7501 tggacaaaaa gcaaagattc cataatataa ggggtcggtg gaccggtcga tgtatgtctt 
     7561 gttgcagatc atcaagaaca cgtagagaaa cccagctgta atcatgcatg gagatacacc 





     7621 tacattgcat gaatatatgt tagatttgca accagagaca actgatctct actgttatga 
     7681 gcaattaaat gacagctcag aggaggagga tgaaatagat ggtccagctg gacaagcaga 
     7741 accggacaga gcccattaca atattgtaac cttttgttgc aagtgtgact ctacgcttcg 
     7801 gttgtgcgta caaagcacac acgtagacat tcgtactttg gaagacctgt taatgggcac 
     7861 actaggaatt gtgtgcccca tctgttctca gaaaccataa tctacc //     
 
 
6.2 Human papillomavirus type 18, complete genome 
ORIGIN       
        1 attaatactt ttaacaattg tagtatataa aaaagggagt aaccgaaaac ggtcgggacc 
       61 gaaaacggtg tatataaaag atgtgagaaa cacaccacaa tactatggcg cgctttgagg 
      121 atccaacacg gcgaccctac aagctacctg atctgtgcac ggaactgaac acttcactgc 
      181 aagacataga aataacctgt gtatattgca agacagtatt ggaacttaca gaggtatttg 
      241 aatttgcatt taaagattta tttgtggtgt atagagacag tataccccat gctgcatgcc 
      301 ataaatgtat agatttttat tctagaatta gagaattaag acattattca gactctgtgt 
      361 atggagacac attggaaaaa ctaactaaca ctgggttata caatttatta ataaggtgcc 
      421 tgcggtgcca gaaaccgttg aatccagcag aaaaacttag acaccttaat gaaaaacgac 
      481 gatttcacaa catagctggg cactatagag gccagtgcca ttcgtgctgc aaccgagcac 
      541 gacaggaacg actccaacga cgcagagaaa cacaagtata atattaagta tgcatggacc 
      601 taaggcaaca ttgcaagaca ttgtattgca tttagagccc caaaatgaaa ttccggttga 
      661 ccttctatgt cacgagcaat taagcgactc agaggaagaa aacgatgaaa tagatggagt 
      721 taatcatcaa catttaccag cccgacgagc cgaaccacaa cgtcacacaa tgttgtgtat 
      781 gtgttgtaag tgtgaagcca gaattgagct agtagtagaa agctcagcag acgaccttcg 
      841 agcattccag cagctgtttc tgaacaccct gtcctttgtg tgtccgtggt gtgcatccca 
      901 gcagtaagca acaatggctg atccagaagg tacagacggg gagggcacgg gttgtaacgg 
      961 ctggttttat gtacaagcta ttgtagacaa aaaaacagga gatgtaatat cagatgacga 
     1021 ggacgaaaat gcaacagaca cagggtcgga tatggtagat tttattgata cacaaggaac 
     1081 attttgtgaa caggcagagc tagagacagc acaggcattg ttccatgcgc aggaggtcca 
     1141 caatgatgca caagtgttgc atgttttaaa acgaaagttt gcaggaggca gcacagaaaa 
     1201 cagtccatta ggggagcggc tggaggtgga tacagagtta agtccacggt tacaagaaat 
     1261 atctttaaat agtgggcaga aaaaggcaaa aaggcggctg tttacaatat cagatagtgg 
     1321 ctatggctgt tctgaagtgg aagcaacaca gattcaggta actacaaatg gcgaacatgg 





     1381 cggcaatgta tgtagtggcg gcagtacgga ggctatagac aacgggggca cagagggcaa 
     1441 caacagcagt gtagacggta caagtgacaa tagcaatata gaaaatgtaa atccacaatg 
     1501 taccatagca caattaaaag acttgttaaa agtaaacaat aaacaaggag ctatgttagc 
     1561 agtatttaaa gacacatatg ggctatcatt tacagattta gttagaaatt ttaaaagtga 
     1621 taaaaccacg tgtacagatt gggttacagc tatatttgga gtaaacccaa caatagcaga 
     1681 aggatttaaa acactaatac agccatttat attatatgcc catattcaat gtctagactg 
     1741 taaatgggga gtattaatat tagccctgtt gcgttacaaa tgtggtaaga gtagactaac 
     1801 agttgctaaa ggtttaagta cgttgttaca cgtacctgaa acttgtatgt taattcaacc 
     1861 accaaaattg cgaagtagtg ttgcagcact atattggtat agaacaggaa tatcaaatat 
     1921 tagtgaagta atgggagaca cacctgagtg gatacaaaga cttactatta tacaacatgg 
     1981 aatagatgat agcaattttg atttgtcaga aatggtacaa tgggcatttg ataatgagct 
     2041 gacagatgaa agcgatatgg catttgaata tgccttatta gcagacagca acagcaatgc 
     2101 agctgccttt ttaaaaagca attgccaagc taaatattta aaagattgtg ccacaatgtg 
     2161 caaacattat aggcgagccc aaaaacgaca aatgaatatg tcacagtgga tacgatttag 
     2221 atgttcaaaa atagatgaag ggggagattg gagaccaata gtgcaattcc tgcgatacca 
     2281 acaaatagag tttataacat ttttaggagc cttaaaatca tttttaaaag gaacccccaa 
     2341 aaaaaattgt ttagtatttt gtggaccagc aaatacagga aaatcatatt ttggaatgag 
     2401 ttttatacac tttatacaag gagcagtaat atcatttgtg aattccacta gtcatttttg 
     2461 gttggaaccg ttaacagata ctaaggtggc catgttagat gatgcaacga ccacgtgttg 
     2521 gacatacttt gatacctata tgagaaatgc gttagatggc aatccaataa gtattgatag 
     2581 aaagcacaaa ccattaatac aactaaaatg tcctccaata ctactaacca caaatataca 
     2641 tccagcaaag gataatagat ggccatattt agaaagtaga ataacagtat ttgaatttcc 
     2701 aaatgcattt ccatttgata aaaatggcaa tccagtatat gaaataaatg acaaaaattg 
     2761 gaaatgtttt tttgaaagga catggtccag attagatttg cacgaggaag aggaagatgc 
     2821 agacaccgaa ggaaaccctt tcggaacgtt taagttgcgt gcaggacaaa atcatagacc 
     2881 actatgaaaa tgacagtaaa gacatagaca gccaaataca gtattggcaa ctaatacgtt 
     2941 gggaaaatgc aatattcttt gcagcaaggg aacatggcat acagacatta aaccaccagg 
     3001 tggtgccagc ctataacatt tcaaaaagta aagcacataa agctattgaa ctgcaaatgg 
     3061 ccctacaagg ccttgcacaa agtcgataca aaaccgagga ttggacactg caagacacat 
     3121 gcgaggaact atggaataca gaacctactc actgctttaa aaaaggtggc caaacagtac 
     3181 aagtatattt tgatggcaac aaagacaatt gtatgaccta tgtagcatgg gacagtgtgt 
     3241 attatatgac tgatgcagga acatgggaca aaaccgctac ctgtgtaagt cacaggggat 
     3301 tgtattatgt aaaggaaggg tacaacacgt tttatataga atttaaaagt gaatgtgaaa 





     3361 aatatgggaa cacaggtacg tgggaagtac attttgggaa taatgtaatt gattgtaatg 
     3421 actctatgtg cagtaccagt gacgacacgg tatccgctac tcagcttgtt aaacagctac 
     3481 agcacacccc ctcaccgtat tccagcaccg tgtccgtggg caccgcaaag acctacggcc 
     3541 agacgtcggc tgctacacga cctggacact gtggactcgc ggagaagcag cattgtggac 
     3601 ctgtcaaccc acttctcggt gcagctacac ctacaggcaa caacaaaaga cggaaactct 
     3661 gtagtggtaa cactacgcct ataatacatt taaaaggtga cagaaacagt ttaaaatgtt 
     3721 tacggtacag attgcgaaaa catagcgacc actatagaga tatatcatcc acctggcatt 
     3781 ggacaggtgc aggcaatgaa aaaacaggaa tactgactgt aacataccat agtgaaacac 
     3841 aaagaacaaa atttttaaat actgttgcaa ttccagatag tgtacaaata ttggtgggat 
     3901 acatgacaat gtaatacata tgctgtagta ccaatatgtt atcacttatt tttttatttt 
     3961 gcttttgtgt atgcatgtat gtgtgctgcc atgtcccgct tttgccatct gtctgtatgt 
     4021 gtgcgtatgc atgggtattg gtatttgtgt atattgtggt aataacgtcc cctgccacag 
     4081 cattcacagt atatgtattt tgttttttat tgcccatgtt actattgcat atacatgcta 
     4141 tattgtcttt acagtaattg tataggttgt tttatacagt gtattgtaca ttgtatattt 
     4201 tgttttatac cttttatgct ttttgtattt ttgtaataaa agtatggtat cccaccgtgc 
     4261 cgcacgacgc aaacgggctt cggtaactga cttatataaa acatgtaaac aatctggtac 
     4321 atgtccacct gatgttgttc ctaaggtgga gggcaccacg ttagcagata aaatattgca 
     4381 atggtcaagc cttggtatat ttttgggtgg acttggcata ggtactggca gtggtacagg 
     4441 gggtcgtaca gggtacattc cattgggtgg gcgttccaat acagtggtgg atgttggtcc 
     4501 tacacgtccc ccagtggtta ttgaacctgt gggccccaca gacccatcta ttgttacatt 
     4561 aatagaggac tccagtgtgg ttacatcagg tgcacctagg cctacgttta ctggcacgtc 
     4621 tgggtttgat ataacatctg cgggtacaac tacacctgcg gttttggata tcacaccttc 
     4681 gtctacctct gtgtctattt ccacaaccaa ttttaccaat cctgcatttt ctgatccgtc 
     4741 cattattgaa gttccacaaa ctggggaggt ggcaggtaat gtatttgttg gtacccctac 
     4801 atctggaaca catgggtatg aggaaatacc tttacaaaca tttgcttctt ctggtacggg 
     4861 ggaggaaccc attagtagta ccccattgcc tactgtgcgg cgtgtagcag gtccccgcct 
     4921 ttacagtagg gcctaccaac aagtgtcagt ggctaaccct gagtttctta cacgtccatc 
     4981 ctctttaatt acatatgaca acccggcctt tgagcctgtg gacactacat taacatttga 
     5041 tcctcgtagt gatgttcctg attcagattt tatggatatt atccgtctac ataggcctgc 
     5101 tttaacatcc aggcgtggga ctgttcgctt tagtagatta ggtcaacggg caactatgtt 
     5161 tacccgcagc ggtacacaaa taggtgctag ggttcacttt tatcatgata taagtcctat 
     5221 tgcaccttcc ccagaatata ttgaactgca gcctttagta tctgccacgg aggacaatga 
     5281 cttgtttgat atatatgcag atgacatgga ccctgcagtg cctgtaccat cgcgttctac 





     5341 tacctccttt gcatttttta aatattcgcc cactatatct tctgcctctt cctatagtaa 
     5401 tgtaacggtc cctttaacct cctcttggga tgtgcctgta tacacgggtc ctgatattac 
     5461 attaccatct actacctctg tatggcccat tgtatcaccc acggcccctg cctctacaca 
     5521 gtatattggt atacatggta cacattatta tttgtggcca ttatattatt ttattcctaa 
     5581 gaaacgtaaa cgtgttccct atttttttgc agatggcttt gtggcggcct agtgacaata 
     5641 ccgtatatct tccacctcct tctgtggcaa gagttgtaaa taccgatgat tatgtgactc 
     5701 ccacaagcat attttatcat gctggcagct ctagattatt aactgttggt aatccatatt 
     5761 ttagggttcc tgcaggtggt ggcaataagc aggatattcc taaggtttct gcataccaat 
     5821 atagagtatt tagggtgcag ttacctgacc caaataaatt tggtttacct gatactagta 
     5881 tttataatcc tgaaacacaa cgtttagtgt gggcctgtgc tggagtggaa attggccgtg 
     5941 gtcagccttt aggtgttggc cttagtgggc atccatttta taataaatta gatgacactg 
     6001 aaagttccca tgccgccacg tctaatgttt ctgaggacgt tagggacaat gtgtctgtag 
     6061 attataagca gacacagtta tgtattttgg gctgtgcccc tgctattggg gaacactggg 
     6121 ctaaaggcac tgcttgtaaa tcgcgtcctt tatcacaggg cgattgcccc cctttagaac 
     6181 ttaaaaacac agttttggaa gatggtgata tggtagatac tggatatggt gccatggact 
     6241 ttagtacatt gcaagatact aaatgtgagg taccattgga tatttgtcag tctatttgta 
     6301 aatatcctga ttatttacaa atgtctgcag atccttatgg ggattccatg tttttttgct 
     6361 tacggcgtga gcagcttttt gctaggcatt tttggaatag agcaggtact atgggtgaca 
     6421 ctgtgcctca atccttatat attaaaggca caggtatgcc tgcttcacct ggcagctgtg 
     6481 tgtattctcc ctctccaagt ggctctattg ttacctctga ctcccagttg tttaataaac 
     6541 catattggtt acataaggca cagggtcata acaatggtgt ttgctggcat aatcaattat 
     6601 ttgttactgt ggtagatacc actcccagta ccaatttaac aatatgtgct tctacacagt 
     6661 ctcctgtacc tgggcaatat gatgctacca aatttaagca gtatagcaga catgttgagg 
     6721 aatatgattt gcagtttatt tttcagttgt gtactattac tttaactgca gatgttatgt 
     6781 cctatattca tagtatgaat agcagtattt tagaggattg gaactttggt gttccccccc 
     6841 ccccaactac tagtttggtg gatacatatc gttttgtaca atctgttgct attacctgtc 
     6901 aaaaggatgc tgcaccggct gaaaataagg atccctatga taagttaaag ttttggaatg 
     6961 tggatttaaa ggaaaagttt tctttagact tagatcaata tccccttgga cgtaaatttt 
     7021 tggttcaggc tggattgcgt cgcaagccca ccataggccc tcgcaaacgt tctgctccat 
     7081 ctgccactac gtcttctaaa cctgccaagc gtgtgcgtgt acgtgccagg aagtaatatg 
     7141 tgtgtgtgta tatatatata catctattgt tgtgtttgta tgtcctgtgt ttgtgtttgt 
     7201 tgtatgattg cattgtatgg tatgtatggt tgttgttgta tgttgtatgt tactatattt 
     7261 gttggtatgt ggcattaaat aaaatatgtt ttgtggttct gtgtgttatg tggttgcgcc 





     7321 ctagtgagta acaactgtat ttgtgtttgt ggtatgggtg ttgcttgttg ggctatatat 
     7381 tgtcctgtat ttcaagttat aaaactgcac accttacagc atccatttta tcctacaatc 
     7441 ctccattttg ctgtgcaacc gatttcggtt gcctttggct tatgtctgtg gttttctgca 
     7501 caatacagta cgctggcact attgcaaact ttaatctttt gggcactgct cctacatatt 
     7561 ttgaacaatt ggcgcgcctc tttggcgcat ataaggcgca cctggtatta gtcattttcc 
     7621 tgtccaggtg cgctacaaca attgcttgca taactatatc cactccctaa gtaataaaac 
     7681 tgcttttagg cacatatttt agtttgtttt tacttaagct aattgcatac ttggcttgta 
     7741 caactacttt catgtccaac attctgtcta cccttaacat gaactataat atgactaagc 
     7801 tgtgcataca tagtttatgc aaccgaaata ggttgggcag cacatactat acttttc   
